APOC3 and familial chylomicronemia syndrome: Volanesorsen, an antisense oligonucleotide targeting APOCIII mRNA, has recently emerged as a promising treatment for refractory or severe hypertriglyceridemia, including patients with familial chylomicronemia syndrome.